[ad_1]
New York, May 12, 2021. Lowey Dannenberg PC, a leading global law firm, is investigating allegations of violations of federal securities laws for investors of Emergent BioSolutions Inc. (“Emergent”). Or “Company”) (New York Stock Exchange:Electronic Business System). If you are a shareholder of Emergent and have a loss of more than $300,000, you should contact the company.
March 31, 2021 New York Times An article published reported that in late February 2021, employees at the emergency manufacturing plant in Baltimore “mixed” the ingredients of different COVID-19 vaccines, contaminating up to 15 million doses of Johnson & Johnson vaccine, forcing regulators to postpone the authorization of the factory’s production line.
April 1, 2021 Associated Press It reported on Emergent’s “violation history” and pointed out that the U.S. Food and Drug Administration (“FDA”) repeatedly cited Emergent to solve problems such as insufficient employee training, broken vials, and mold and other contamination in the facility.
April 3, 2021 New York Times According to the report, the Biden administration appointed Johnson & Johnson as the Baltimore plant in a state of emergency and prohibited it from producing AstraZeneca vaccines. This is for the company that touted its “unique” preparation and “proven manufacturing capabilities” a few months ago. It was a setback.
On this news, the company’s share price fell by US$14.29 per share in two consecutive trading days, a decline of more than 15%, and closed at US$78.62 per share on April 5, 2021.
The complaint stated that the defendant did not disclose to investors: (i) The Baltimore plant in the emergency had a history of manufacturing problems, which increased the possibility of large-scale pollution; (ii) In Emergent’s plant, these long-standing pollution risks and quality Control issues have led to a series of FDA citations; (iii) After the workers in the Baltimore plant deviated from manufacturing standards, the company had to discard millions of doses of COVID-19 vaccine; The public statement of the ability to produce multiple COVID-19 vaccines on a large scale at its Baltimore production site is essentially false and/or misleading, and/or lacks a reasonable basis.
If you are a shareholder of Emergent and purchased Emergent securities between July 6, 2020 and March 31, 2021 (inclusive), you must request the court to appoint you as such before June 18, 2021 Chief plaintiff.To participate, learn more or discuss questions about the investigation, please contact our lawyers at (914) 733-7256, or contact us via email surveys@lowey.com.
Reporter: People with non-emergency non-public information should consider their options to help with investigations or use the SEC whistleblower program. According to the new plan, whistleblowers who provide original information may receive a total of up to 30% of the SEC’s successful recovery.
About Roy Dannenberg
Lowey Dannenberg, a state-owned company representing institutions and individual investors, suffered financial losses due to corporate fraud and malfeasance in violation of federal securities and antitrust laws. The company has extensive experience in prosecuting multi-million dollar lawsuits and has previously recovered billions of dollars on behalf of investors.
contact
Lowey Dannenberg PC
Suite 1100, 44 South Broadway
White Plains, New York 10601
Phone: (914) 733-7256
e-mail: surveys@lowey.com
[ad_2]
Source link
